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Platelet-derived growth factor receptor β (PDGFRβ) belongs to a subfamily of receptor 
tyrosine kinases (RTKs). The PDGFRs are a family of growth factor ligands PDGF AA, AB, BB, CC, 
and DD additionally, PDGFRα and PDGFRβ are two types of PDGFRs. It possesses an outer 
membrane with a PDGF ligand binding site and an inner membrane tyrosine kinase (TK) domain 
with an adenosine triphosphate (ATP) binding site. Binding of PDGF ligands to the extracellular 
binding domain triggers PDGFRβ dimerization, thus inducing phosphorylation in intracellular 
domain. This is followed by the activation of signaling pathways that regulate important cellular 
functions. Upregulation of PDGFRβ in numerous human tumors and its relationship with tumor 
progression features such as cell migration, metastasis, angiogenesis, and proliferation, have been 
reported. PDGFRβ expression in normal cells is highly restricted; however, its upregulation was 
found in the various malignant tumor. Therefore, PDGFRβs can be an attarctive target not only for 
cancer therapy but also for developing tumor-imaging agents.  
Nuclear medicine is a revolutionized invention not only in cancer research but also in drug 
development, which can be utilized to investigate disease noninvasively as well as facilitate 
monitoring disease progression or response to therapy repeatedly. Quantification of receptor density 
is meaningful because it allows disease diagnosis as well as monitoring the effectiveness of therapy. 
Single photon emission computed tomography (SPECT) and positron emission tomography (PET) 
are molecular imaging modalities which allow expression assessment of molecular targets within 
living organism. Although PET has better sensitivity and spatial resolution, SPECT has advantages 
such as more available, widely used, and cheaper than PET. 
1-{2-[5-(2-Methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}piperidin-4-amine 
(CP-673451, IQP) (Fig. 1), is a derivative of benzimidazole. It is a potent PDGFRβ inhibitor which 
inhibits phosphorylation of cells with high selectivity relative to many other subfamilies of receptor 
tyrosine kinases (IC50 = 1.0 nM). IQP targeted ATP binding site as tumor therapeutic target. Using 
this scaffold to develop PDGFRβ imaging agents might be meaningful to visualize intracellular part 
of the molecular target. 
 
Figure 1. Chemical structures of IQP (12) and its radiolabeled derivatives [125I]IIQP (20), [125I]IB-IQP (21), 
[77Br]BrIQP (25), [77Br]BrB-IQP(26), [125I]I-Q1 (40), and [125I]I-Q2 (41). 
 
The purpose of this study was to develop the radiohalogenated derivatives of IQP as new 
radiotracers for imaging of the PDGFRβ expressing tumors. 
This manuscript is divided into three chapters. Chapter 1 described the synthesis and 
evaluation of radioiodinated 
1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}piperidin-4-amine derivatives 
for PDGFRβ imaging. Iodine was introduced into IQP scaffold directly at the C-5 of quinoline core 
of IQP and indirectly by conjugation wherein amine group of piperidine was linked with 
3-iodobenzoyl group using ATE (N-succinimidyl-3-iodobenzoate). Radioiodinated compounds 
[125I]IIQP and [125I]IB-IQP were synthesized using tin precursors under non-carrier added condition 
and N-chlorosuccinimide (NCS) as an oxidizing agent. In this study, 125I was used as an alternative 
radionuclide instead of 123I and 124I, which are radionuclide for SPECT and PET, respectively. 
Chapter 2 described Synthesis and evaluation of radiobrominated benzimidazole-quinoline 
derivatives as new candidate PET probes for PDGFRβ. Not only radioiodination, but also 
radiobromination of IQP scaffold have been achieved using 77Br. In this initial study, 77Br was 
utilized because it has relatively long half-life compared to 76Br, which is a radionuclide for PET. 
Chapter 3 described the synthesis and preliminary biological evaluation of radioiodinated 
benzimidazole-quinoline derivatives as PDGFRβ imaging probes. In an effort to modify the scaffold 
structure of benzimidazole-quinoline, nine new compounds were designed in which a variety of side 
chain was introduced into C-8 of quinoline core instead of piperidine group in IQP. Hereafter, 
iodinated compounds were synthesized in order to assess their feasibility as imaging agents using 
iodine as radionuclide. 
Evaluation of these compounds by in vitro stability, in vitro cellular uptake, blocking studies, 








ブ の 開 発 を 目 的 に 、 PDGFRβ の 阻 害 剤 で あ る 1-(2-(5-(2-methoxyethoxy)- 
1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine (CP-673451, IQP)をリード化合物とし
て、誘導体を設計、合成した。次いで、放射標識を行い、標識体の有用性を評価した。その結果、
in vitro、in vivo において、放射標識 IQP 誘導体は、PDGFRβ 発現癌細胞に高く取り込まれ、その
取込は過剰量の IQP により阻害された。つまり、本プローブが PDGFRβ イメージングに有用であ
る可能性が示された。これまでに PDGFRβ チロシンキナーゼ部位を標的としたイメージングプロー
ブは開発されておらず、本研究の新規性は高く、受容体チロシンキナーゼイメージングプローブ開
発に有益な情報を与えるものである。以上より、本論文は博士（学術）に値すると判断される。 
 
